Stellate Ganglion Block for Post-Traumatic Stress Disorder

"Candidates seeking to participate in this clinical trial must be afflicted with post-traumatic stress disorder and fall within the age range of 18 to 65 years. A total of 140 participants are being sought for recruitment into the study."

"Indeed, information from clinicaltrials.gov confirms the active recruitment status of this investigation. The trial was initially listed on 26th February 2024 and most recently revised on 28th February 2024. Recruitment is underway for a total of 140 participants at one designated site."

"To be eligible for this trial, potential participants must have reached the age of consent but not exceed 65 years old."

"Yes, information on clinicaltrials.gov highlights that this study is actively seeking eligible individuals. This trial was initially posted on February 26th, 2024 and had its latest update on February 28th, 2024. The aim is to enroll a total of 140 participants from one designated site."

"As per our evaluation at Power, the safety rating for Stellate Ganglion Block stands at 2 on a scale of 1 to 3. This assessment is based on the current Phase 2 trial data which indicates some degree of safety but lacks evidence regarding efficacy."

"The principal aim of this investigation, to be scrutinized during baseline and at 1-month, 3-month, and 6-month follow-up evaluations is the alteration in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5) scores from initiation. Secondary objectives incorporate changes in Psychophysiological arousal assessed via Interbeat Interval derived from smartwatch data, alterations in self-blame and negative cognitions as measured by the Posttraumatic Cognitions Inventory (PTCI), which ranges between a score of 33 to 231 with higher values indicating more severe maladaptive beliefs; additionally, shifts in skin temperature recorded through"